2005
DOI: 10.1002/eji.200526123
|View full text |Cite
|
Sign up to set email alerts
|

Fulminant experimental autoimmune encephalo-myelitis induced by retrovirally mediated TCR gene transfer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2008
2008
2010
2010

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 41 publications
(54 reference statements)
0
4
0
Order By: Relevance
“…Several envisioned gene therapy applications require expression of multiple proteins in T cells. The most obvious of these would be the introduction of pre-rearranged TCRα and TCRβ chains that, together, would encode a receptor targeting diseased cells [32][34].…”
Section: Discussionmentioning
confidence: 99%
“…Several envisioned gene therapy applications require expression of multiple proteins in T cells. The most obvious of these would be the introduction of pre-rearranged TCRα and TCRβ chains that, together, would encode a receptor targeting diseased cells [32][34].…”
Section: Discussionmentioning
confidence: 99%
“…Delivery of tumor-specific TCR genes into hematopoietic stem cells constitutes a recent promising strategy in this direction (7,8). Antigen-specific T cells may also be provided by infusion of lymphoid progenitors that are educated and tolerized according to the recipient's genetic background (45).…”
Section: Discussionmentioning
confidence: 99%
“…Thus, a major limitation of T cell transgenesis is the difficulty in teasing apart the postdevelopmental functions of genes from effects on T cell development, when transgenes are placed under the control of T lineage enhancer/promoters, such as those derived from the Lck, Cd4, or CD2 genes (4)(5)(6). Segregating thymic versus post-thymic effects of transgene expression would also be useful to target gene products such as tumor antigen-specific TCRs to post-thymic T cells without perturbing thymocyte development and selection, which could result from the expression of autoreactive, high-affinity TCRs (7,8).…”
Section: Introductionmentioning
confidence: 99%
“…137,138 T cells expressing ␥␦TCR are another lymphocyte population with endogenous killing ability that has been modified to express CAR, and these cells can be selectively proliferated using an aminobiphosphonate (Zoledronate), 139 raising the possibility that a Food and Drug Administration (FDA)-approved pharmacologic agent can be used to selectively propagate these infused CAR ϩ T cells in vivo. Instead of genetically modifying mature lymphocytes to express CAR, investigators have introduced CAR into developing thymocytes 140 and immunoreceptors into hematopoietic stem cells (HSC) [141][142][143] to avoid negative selection and improve immune-mediated surveillance. The approach of genetically modifying lymphoid precursors has also been adapted by Zakrzewski et al to make "universal T cells" in which CAR ϩ HSC can be adoptively transferred across MHC barriers.…”
Section: Expressing Cars In Cells Other Than ␣␤ Tcr ؉ T Cellsmentioning
confidence: 99%